Clinical Trial Update: 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating 9MW2821 plus toripalimab versus 9MW2821 alone as first-line treatment for locally advanced or metastatic urothelial carcinoma; recruitm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma
• Urothelial Carcinoma of the Bladder
• Urothelial Carcinoma of the Renal Pelvis and Ureter

Drugs mentioned

• 9MW2821
• Toripalimab (Toripalimab)

Snippet

Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. | Conditions: Urothelial Carcinoma, Urothelial Carcinoma Bladder | Phase 2 | Status: RECRUITING